Categories: All postsCannabis

The Green Organic Dutchman’s stock is in serious trouble, this investor says

A lot has changed in the cannabis space since last spring when The Green Organic Dutchman (The Green Organic Dutchman Stock Quote, Chart TSX:TGOD) appeared on the scene with the largest-ever IPO for a Canadian pot company. And while the company continues with its expansion plans, its share price is looking rougher by the day, a scenario which should be speaking volumes to investors, says Jeff Parent, chief investment officer at CastleMoore Inc, who says that until there’s some serious indications of a turnaround, investors should stay clear of TGOD.

With a marketing edge touting its organic bona fides and ambitions to become a top-five producer in terms of sheer volume, The Green Organic Dutchman caught the cannabis wave just right when it listed on the TSX in May of 2018 by raising $132 million.

“We are extremely pleased with the market’s support of our IPO, which is the largest to date on the TSX in the cannabis space,” said then-CEO Robert Anderson. “The additional funds will support the Company’s plans of becoming the world’s leading brand of organic cannabis.”

Those ambitious plans include gunning for 170,000 kg of cannabis production per year through build-outs in Ontario, Quebec and Jamaica. But while expansion plans and sky high capacity projections have been par for the course in cannabis, these days investors appear to be less willing to take a flyer on yet-to-be-realized companies like TGOD, as witnessed by its share price. After its initial offering at $3.65, TGOD shot up to more than $10.00 by mid-September but has been on a downward slide ever since and currently trades in the $2 range. That trajectory may not look much different from many other pot companies whose stocks ran up in the days before legalization in Canada, but TGOD looks particularly ominous, says Parent, who recently spoke of the stock from a technical perspective on BNN Bloomberg.

“When a stock loses this much, it’s on life-support,” says Parent. “[Cannabis] stocks have been very tricky to begin with but this one in particular does not look good and I wouldn’t be a buyer until it shows some signs of life. You’d want to see a breakout with some volume and then that’s when I’d trigger a buy.”

“If you’re holding onto it, maybe consider reducing it,” he says. “I’m not saying that the stock is going to go bankrupt, but it’s certainly not heading in the right direction and it hasn’t been for a while. And there’s not been a lot of support in it so nothing positive, technically.”

TGOD last reported its financials on November 13 for the quarter ended September 30, 2018, featuring a loss of $10 million in operating expenses over the quarter and no revenue to report.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: tgod
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 hours ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

3 hours ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

1 day ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

1 day ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

1 day ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

4 days ago